Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic efficacy against Mycobacterium tuberculosis using ID93 and liposomal adjuvant formulations
Susan L. Baldwin, Valerie A. Reese, Sasha E. Larsen, et al.
Frontiers in Microbiology (2022) Vol. 13
Open Access | Times Cited: 11

Showing 11 citing articles:

Immunological effects of the PE/PPE family proteins of Mycobacterium tuberculosis and related vaccines
Fangzheng Guo, Jing Wei, Yamin Song, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Role of PE family of proteins in mycobacterial virulence: Potential on anti-TB vaccine and drug design
Priyanka Dahiya, Manoj Kumar Bisht, Sangita Mukhopadhyay
International Reviews of Immunology (2025), pp. 1-16
Closed Access
The Role and Potential Application of IL-12 in the Immune Regulation of Tuberculosis
H J Wang, Guiren Ruan, Yuanchun Li, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 3106-3106
Open Access
Characterizing TLR4 agonist EmT4™ as an anti-Mycobacterium tuberculosis vaccine adjuvant
Sasha E. Larsen, Maham Rais, Valerie A. Reese, et al.
ImmunoHorizons (2025) Vol. 9, Iss. 6
Open Access
Role of vesicular nanocarriers for the treatment of tuberculosis
Brojendra Nath Saren, Sayali Dighe, Saroj Kumar Jha, et al.
Elsevier eBooks (2025), pp. 99-145
Closed Access
Protective Efficacy and Immunogenicity of Rv0351/Rv3628 Subunit Vaccine Formulated in Different Adjuvants Against Mycobacterium tuberculosis Infection
Kee Woong Kwon, Tae Gun Kang, Ara Lee, et al.
Immune Network (2023) Vol. 23, Iss. 2
Open Access | Times Cited: 8
Enhancing TB Vaccine Efficacy: Current Progress on Vaccines, Adjuvants and Immunization Strategies
Hui Wang, Shuxian Wang, Fang Ren, et al.
Vaccines (2023) Vol. 12, Iss. 1, pp. 38-38
Open Access | Times Cited: 7
Immunogenicity and protection against Mycobacterium avium with a heterologous RNA prime and protein boost vaccine regimen
Maham Rais, Hazem F. M. Abdelaal, Valerie A. Reese, et al.
Tuberculosis (2022) Vol. 138, pp. 102302-102302
Open Access | Times Cited: 12
Protective interplay: Mycobacterium tuberculosis diminishes SARS-CoV-2 severity through innate immune priming
Brittany D. Williams, Debora Ferede, Hazem F. M. Abdelaal, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Development of semisynthetic saponin immunostimulants
Di Bai, Hyun Jung Kim, Pengfei Wang
Medicinal Chemistry Research (2024) Vol. 33, Iss. 8, pp. 1292-1306
Open Access
Co-regulation of innate and adaptive immune responses induced by ID93+GLA-SE vaccination in humans
Andrew Fioré-Gartland, Himangi Srivastava, Aaron Seese, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Page 1

Scroll to top